Cargando…

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas

SIMPLE SUMMARY: To differentiate IDH-mutant grade 4 astrocytomas from IDH-wild-type glioblastomas, two MRI sequences (post-contrast T1 and T2-FLAIR) were acquired from 57 patients. The images were resliced, resampled, and realigned. In the next step, tumors were segmented semi-automatically into sub...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hosseini, Seyyed Ali, Hosseini, Elahe, Hajianfar, Ghasem, Shiri, Isaac, Servaes, Stijn, Rosa-Neto, Pedro, Godoy, Laiz, Nasrallah, MacLean P., O’Rourke, Donald M., Mohan, Suyash, Chawla, Sanjeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913426/ https://www.ncbi.nlm.nih.gov/pubmed/36765908 http://dx.doi.org/10.3390/cancers15030951

Ejemplares similares

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1
por: Rathore, Saima, et al.
Publicado: (2018)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

Rare Cases of IDH1 Mutations in Spinal Cord Astrocytomas
por: Konovalov, N. A., et al.
Publicado: (2020)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla
por: Verma, Gaurav, et al.
Publicado: (2016)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Synergistic impact of motion and acquisition/reconstruction parameters on (18)F‐FDG PET radiomic features in non‐small cell lung cancer: Phantom and clinical studies
por: Hosseini, Seyyed Ali, et al.
Publicado: (2022)

LOX Expression and Functional Analysis in Astrocytomas and Impact of IDH1 Mutation
por: da Silva, Roseli, et al.
Publicado: (2015)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Radiomics-based prediction of multiple gene alteration incorporating mutual genetic information in glioblastoma and grade 4 astrocytoma, IDH-mutant
por: Sohn, Beomseok, et al.
Publicado: (2021)

The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas
por: Christians, Arne, et al.
Publicado: (2019)

Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas
por: Liu, Yan, et al.
Publicado: (2022)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging
por: Yang, Xiefeng, et al.
Publicado: (2022)

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting
por: Rautajoki, Kirsi J., et al.
Publicado: (2023)

Clinical Evaluation of IDH Mutation Status in Formalin-Fixed Paraffin-Embedded Tissue in Gliomas
por: Nelson, Ernest J., et al.
Publicado: (2023)

Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas
por: de Godoy, Laiz Laura, et al.
Publicado: (2023)

Predicting IDH genotype in gliomas using FET PET radiomics
por: Lohmann, Philipp, et al.
Publicado: (2018)

IDH mutation-specific radiomic signature in lower-grade gliomas
por: Liu, Xing, et al.
Publicado: (2019)

Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas
por: Mäkelä, Katri, et al.
Publicado: (2014)

MPC-07 MECHANISMS OF BETTER PROGNOSIS IN IDH-MUTATED ASTROCYTOMA WITH 19Q-LOSS
por: Otani, Ryohei, et al.
Publicado: (2019)

IDH-mutant astrocytoma with EGFR amplification—Genomic profiling in four cases and review of literature
por: Umphlett, Melissa, et al.
Publicado: (2022)

Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma
por: Shi, Diana D., et al.
Publicado: (2023)

Multicenter DSC–MRI-Based Radiomics Predict IDH Mutation in Gliomas
por: Manikis, Georgios C., et al.
Publicado: (2021)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

IDH‐mutated astrocytomas with 19q‐loss constitute a subgroup that confers better prognosis
por: Otani, Ryohei, et al.
Publicado: (2018)

MPC-11 Comprehensive gene expression analysis of IDH-mutated astrocytomas with 19q-loss
por: Otani, Ryohei, et al.
Publicado: (2020)

PATH-14. GENETIC SUSCEPTIBILITY AND OUTCOMES OF PEDIATRIC, ADOLESCENT AND YOUNG ADULT IDH-MUTANT ASTROCYTOMAS
por: Bornhorst, Miriam, et al.
Publicado: (2020)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

NI-1 METHYLTHIOADENOSINE PHOSPHOLYLASE STATUS CORRELATES WITH PROGNOSIS AND METHIONINE UPTAKE IN IDH MUTANT ASTROCYTOMA
por: Yamamura, Toshihiro, et al.
Publicado: (2022)

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
por: Weller, Jonathan, et al.
Publicado: (2022)

Metabolic biomarkers of radiotherapy response in plasma and tissue of an IDH1 mutant astrocytoma mouse model
por: Ruiz-Rodado, Victor, et al.
Publicado: (2022)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

Multi-institutional noninvasive in vivo characterization of IDH, 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk)
por: Rathore, Saima, et al.
Publicado: (2021)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hsa535ta27khrgojhgk4vb780o